TRANSCENTA-B (06628) Announces Milestone Payment for HiCB Out-Licensing and Steady Growth in CDMO Operations

Stock News05-26

TRANSCENTA-B (06628) has announced that the company has received a milestone payment of RMB 7 million from the out-licensing of its HiCB (High-Intensity Continuous Bioprocessing) platform, while its CDMO business has also made significant progress. Following the strategic collaboration and non-exclusive technology license agreement signed with EirGenix Inc. (TWSE: 6589) by the end of 2025, along with the receipt of the associated upfront payment, the two companies have achieved a major technical milestone, triggering the first milestone payment. To date, TRANSCENTA has successfully completed key deliverables. The collaboration is progressing steadily, with the goal of implementing HiCB technology for GMP production at EirGenix's facilities. To further advance the commercialization of the HiCB platform, TRANSCENTA recently appointed its former Chief Technology Officer (CTO), Dr. Huang Guangcheng, as the Global Partnership Lead for the HiCB platform. He will lead the global technology out-licensing strategy and oversee platform implementation. Under his leadership, TRANSCENTA will continue to expand this non-exclusive licensing model, which allows the company to retain full technology ownership while generating revenue through licensing fees, customized CHO medium optimization services, and ongoing medium supply. The proceeds will be reinvested in platform upgrades and core R&D pipelines. Concurrently, TRANSCENTA's CDMO business has also achieved steady progress. The company has recently signed new service contracts utilizing its HiCB process for bioprocessing technology to produce GMP Drug Substance (DS) for complex biologics and GMP Drug Product (DP) for siRNA projects. TRANSCENTA is also currently negotiating contracts for other high-potential projects, including integrated IND development programs, siRNA GMP drug product manufacturing, developability assessments, and material production for global clients. With advancements in the HiCB out-licensing initiatives and the continued expansion of its CDMO business, TRANSCENTA remains well-positioned to drive sustainable growth and create long-term value for its partners and shareholders.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment